

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**DISCLOSEABLE TRANSACTION**  
**PURCHASE OF STRUCTURED DEPOSITS**

**PURCHASE OF STRUCTURED DEPOSITS**

The Board announces that on November 19, 2021, the Company entered into (i) the SPD Structured Deposit Agreement VIII with SPD Bank, pursuant to which the Company agreed to purchase structured deposit in the principal amount of RMB400 million from SPD Bank; and (ii) the CITIC Structured Deposit Agreement IV with China CITIC Bank, pursuant to which the Company agreed to purchase structured deposit in the principal amount of RMB300 million from China CITIC Bank.

**LISTING RULES IMPLICATIONS**

As all of the applicable percentage ratios (as calculated under Rule 14.07 of the Listing Rules) in respect of the transaction contemplated under the SPD Structured Deposit Agreement VIII were below 5%, the purchase of structured deposit under the SPD Structured Deposit Agreement VIII does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules on a standalone basis. As the SPD Structured Deposit Agreement VIII was entered into with the same bank and the transaction thereunder is of a similar nature as the transaction under the SPD Structured Deposit Agreement VII (which remains outstanding as of the date of this announcement), the transactions contemplated under the SPD Structured Deposit Agreements shall be aggregated pursuant to Rule 14.22 of the Listing Rules.

As all of the applicable percentage ratio (as calculated under Rule 14.07 of the Listing Rules) in respect of the transaction contemplated under the CITIC Structured Deposit Agreement IV were below 5%, the purchase of structured deposit under the CITIC Structured Deposit Agreement IV does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules on a standalone basis. As the CITIC Structured Deposit Agreement IV was entered into with the same bank and the transaction thereunder is of a similar nature as the transactions under the CITIC Structured Deposit Agreement II and CITIC Structured Deposit Agreement III (which remain outstanding as of the date of this announcement), the transactions contemplated under the CITIC Structured Deposit Agreements shall be aggregated pursuant to Rule 14.22 of the Listing Rules.

As the highest applicable percentage ratio in respect of the purchase of structure deposits under each of the SPD Structured Deposit Agreements and the CITIC Structured Deposit Agreements, each on an aggregate basis, exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of structured deposits under each of the SPD Structured Deposit Agreements and the CITIC Structured Deposit Agreements constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the notification and announcement requirements under Chapter 14 of the Listing Rules.

## INTRODUCTION

Reference is made to the announcements of the Company in respect of the purchase of structured deposit from SPD Bank dated November 11, 2021 and the purchase of structured deposits from China CITIC Bank dated October 28, 2021, respectively.

The Board announces that on November 19, 2021, the Company entered into (i) the SPD Structured Deposit Agreement VIII with SPD Bank, pursuant to which the Company agreed to purchase structured deposit in the principal amount of RMB400 million from SPD Bank; and (ii) the CITIC Structured Deposit Agreement IV with China CITIC Bank, pursuant to which the Company agreed to purchase structured deposit in the principal amount of RMB300 million from China CITIC Bank.

## THE STRUCTURED DEPOSIT AGREEMENTS

The principal terms of the SPD Structured Deposit Agreement VIII and CITIC Structured Deposit Agreement IV are set out as follows:

<b>Agreement</b>	SPD Structured Deposit Agreement VIII	CITIC Structured Deposit Agreement IV
<b>Date of purchase</b>	November 19, 2021	November 19, 2021
<b>Parties</b>	(a) The Company; and (b) SPD Bank.	(a) The Company; and (b) China CITIC Bank.
<b>Name of the product</b>	SPD Bank Li Duo Duo Company Stable Profit 21JG8163 (Bullish Three-tier) RMB-denominated Structured Deposit Product* (上海浦東發展銀行利多多公司穩利21JG8163期(三層看漲)人民幣對公結構性存款)	Win-Win Wisdom Credit Exchange Rate Linked 07162th RMB Structured Deposit Product* (共贏智信匯率掛鉤人民幣結構性存款07162期)
<b>Type of return</b>	Principal-guaranteed with variable return	Principal-guaranteed with variable return and closed-end structured deposit
<b>Purchase amount</b>	RMB400 million  The Company is of the view that the consideration of such purchase was determined on the basis of arm's length commercial terms.	RMB300 million  The Company is of the view that the consideration of such purchase was determined on the basis of arm's length commercial terms.

	<p>The structured deposit was purchased with the funds redeemed upon maturity of the structured deposit purchased under the SPD Structured Deposit Agreement IV, without using the H-Share IPO proceeds of the Company.</p>	<p>The structured deposit was purchased with the funds redeemed upon maturity of the structured deposit purchased under the CITIC Structured Deposit Agreement I, without using the H-Share IPO proceeds of the Company.</p>
<b>Term of deposit</b>	<p>From November 22, 2021 to February 22, 2022</p>	<p>From November 20, 2021 to February 18, 2022</p>
<b>Expected annualized floating rate of return</b>	<p>The initial price is the EUR-USD Bloomberg foreign exchange fixing rate to be published on the “EUR CURRENCY BFIX” page of the website of Bloomberg at 10:00 a.m. (Beijing time) on November 23, 2021.</p> <p>The observation price is the EUR-USD Bloomberg foreign exchange fixing rate to be published on the “EUR CURRENCY BFIX” page of the website of Bloomberg at 2:00 p.m. (Beijing time) on February 16, 2022.</p> <p>The expected annualized floating rate of return will be 0% per annum if the observation price is less than 94.30% of the initial price.</p> <p>The expected annualized floating rate of return will be 1.80% per annum if the observation price is equal to or higher than 94.30% but less than 102.30% of the initial price.</p> <p>The expected annualized floating rate of return will be 2.00% per annum if the observation price is equal to or higher than 102.30% of the initial price.</p>	<p>The initial price is the USD-JPY Bloomberg foreign exchange fixing rate to be published on the “USDJPY CURRENCY BFIX” page of the website of Bloomberg at 3:00 p.m. (Tokyo time) on November 22, 2021.</p> <p>The observation price is the USD-JPY Bloomberg foreign exchange fixing rate to be published on the “USDJPY CURRENCY BFIX” page of the website of Bloomberg at 3:00 p.m. (Tokyo time) on February 15, 2022.</p> <p>The expected annualized rate of return will be 3.65% per annum if the observation price increased over 2.00% from the initial price.</p> <p>The expected annualized rate of return will be 3.25% per annum if the observation price increased less than 2.00% (inclusive) from the initial price or decreased less than 7.00% (inclusive) from the initial price.</p> <p>The expected annualized rate of return will be 1.48% per annum if the observation price decreased over 7.00% from the initial price.</p>

<b>Principle for calculation of return and interest</b>	Expected return = principal × (guaranteed return rate (1.40%) + annualized floating rate of return) × number of days of interest accrual ÷ 360; actual return is calculated based on simple interest	Expected return = principal × expected annualized rate of return × number of days of interest accrual ÷ 365
<b>Right of early termination</b>	<p>The Company has no right of early termination (redemption) for this product.</p> <p>SPD Bank has the right to early terminate this product according to the actual investment situation without further notice to the customers, provided that it shall publish an information announcement at its branches, or websites or in other means within two working days before the date of early termination.</p>	<p>The Company has no right of early termination (redemption) for this product.</p> <p>China CITIC Bank has the right of early termination upon occurrence of, among others, material changes in laws or regulations or market conditions, provided that it shall publish an announcement thereof at its branches, websites or elsewhere within two working days after such events become known to it, and remit the principal and return (if any) to the Company within two business days upon termination.</p>
<b>Payment of principal and return</b>	The principal and the return of the product will be paid on the maturity date of the product.	The principal and the return of the product will be paid on the maturity date of the product.

## INFORMATION ON THE PARTIES

### The Company

The Company is dedicated to exploring best solutions to the prevention of infectious diseases through engaging in research & development, manufacturing and commercialization of high quality vaccine products for human use worldwide.

### SPD Bank

SPD Bank is a licensed bank in the PRC and a joint stock company established under the laws of the PRC, which provides corporate and personal banking business, treasury business, finance leasing, asset management and other financial services in the PRC. Its shares are listed on the Shanghai Stock Exchange (stock code: 600000). To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, SPD Bank and its ultimate beneficial owners are parties independent of the Company and its connected persons as of the date of this announcement.

## **China CITIC Bank**

China CITIC Bank is a licensed bank in the PRC and a joint stock company established under the laws of the PRC, which provides a full range of financial products and services to its customers nationwide, with corporate banking, private banking and financial market operations being its principal business activities. Its H shares are listed on the Stock Exchange (stock code: 0998) and A shares are listed on the Shanghai Stock Exchange (stock code: 601998). To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, China CITIC Bank and its ultimate beneficial owners are parties independent of the Company and its connected persons as of the date of this announcement.

## **REASONS FOR AND BENEFITS OF THE PURCHASE OF STRUCTURED DEPOSIT**

The Company is of the view that the reasonable and efficient use of temporary idle funds will enhance the overall capital gain of the Company, which is consistent with the core objectives of the Company to ensure capital safety and liquidity. The impact of risk factors on the expected rates of return of each of the SPD Structured Deposit Agreement VIII and CITIC Structured Deposit Agreement IV is low, but the Group could get a higher return as compared with fixed term deposit in commercial banks in the PRC.

The Directors consider that the terms of each of the SPD Structured Deposit Agreement VIII and CITIC Structured Deposit Agreement IV and the transactions contemplated thereunder are fair and reasonable, on normal commercial terms or better and in the ordinary course of business of the Group, and are in the interests of the Company and its shareholders as a whole.

## **LISTING RULES IMPLICATIONS**

As all of the applicable percentage ratios (as calculated under Rule 14.07 of the Listing Rules) in respect of the transaction contemplated under the SPD Structured Deposit Agreement VIII were below 5%, the purchase of structured deposit under the SPD Structured Deposit Agreement VIII does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules on a standalone basis. As the SPD Structured Deposit Agreement VIII was entered into with the same bank and the transaction thereunder is of a similar nature as the transaction under the SPD Structured Deposit Agreement VII (which remains outstanding as of the date of this announcement), the transactions contemplated under the SPD Structured Deposit Agreements shall be aggregated pursuant to Rule 14.22 of the Listing Rules.

As all of the applicable percentage ratio (as calculated under Rule 14.07 of the Listing Rules) in respect of the transaction contemplated under the CITIC Structured Deposit Agreement IV were below 5%, the purchase of structured deposit under the CITIC Structured Deposit Agreement IV does not constitute a discloseable transaction of the Company under Chapter 14 of the Listing Rules on a standalone basis. As the CITIC Structured Deposit Agreement IV was entered into with the same bank and the transaction thereunder is of a similar nature as the transactions under the CITIC Structured Deposit Agreement II and CITIC Structured Deposit Agreement III (which remain outstanding as of the date of this announcement), the transactions contemplated under the CITIC Structured Deposit Agreements shall be aggregated pursuant to Rule 14.22 of the Listing Rules.

As the highest applicable percentage ratio in respect of the purchase of structure deposits under each of the SPD Structured Deposit Agreements and CITIC Structured Deposit Agreements, each on an aggregate basis, exceeds 5% but all of the applicable percentage ratios are less than 25%, the purchase of structured deposits under each of the SPD Structured Deposit Agreements and CITIC Structured Deposit Agreements constitutes a discloseable transaction of the Company under Chapter 14 of the Listing Rules and is subject to the notification and announcement requirements under Chapter 14 of the Listing Rules.

## DEFINITIONS

Unless the context otherwise requires, the capitalized terms used herein shall have the following meanings:

“Board”	the board of Directors
“China CITIC Bank”	China CITIC Bank Corporation Limited, a joint stock company incorporated in the PRC with limited liability and a licensed bank in the PRC, whose H shares are listed on the Stock Exchange (stock code: 0998) and A shares are listed on the Shanghai Stock Exchange (stock code: 601998)
“CITIC Structured Deposit Agreement I”	the structured deposit agreement entered into between the Company and China CITIC Bank dated August 20, 2021 in relation to the purchase of structured deposit in the principal amount of RMB300 million
“CITIC Structured Deposit Agreement II”	the structured deposit agreement entered into between the Company and China CITIC Bank dated August 30, 2021 in relation to the purchase of structured deposit in the principal amount of RMB140 million
“CITIC Structured Deposit Agreement III”	the structured deposit agreement entered into between the Company and China CITIC Bank dated October 28, 2021 in relation to the purchase of structured deposit in the principal amount of RMB200 million
“CITIC Structured Deposit Agreement IV”	the structured deposit agreement entered into between the Company and China CITIC Bank dated November 19, 2021 in relation to the purchase of structured deposit in the principal amount of RMB300 million
“CITIC Structured Deposit Agreements”	the CITIC Structured Deposit Agreement II, the CITIC Structured Deposit Agreement III and the CITIC Structured Deposit Agreement IV



“Company”	CanSino Biologics Inc. (康希諾生物股份公司), a joint stock company incorporated in the PRC with limited liability on February 13, 2017, the H Shares of which are listed on the Main Board of The Stock Exchange of Hong Kong Limited (stock code: 6185) and the A Shares of which are listed on Sci-Tech Innovation Board of the Shanghai Stock Exchange (stock code: 688185)
“connected person”	has the meaning ascribed to it in the Listing Rules
“Directors”	the director(s) of the Company
“EUR”	Euro, the lawful currency of the member states of the European Union
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“H-Share IPO”	initial public offering of the H shares of the Company
“JPY”	Japanese Yen, the lawful currency of Japan
“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“PRC”	the People’s Republic of China, and for the purpose of this announcement only, excluding Hong Kong, the Macau Special Administrative Region and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“SPD Bank”	Shanghai Pudong Development Bank Co., Ltd., a joint stock company incorporated in the PRC with limited liability and a licensed bank in the PRC, whose shares are listed on the Shanghai Stock Exchange (stock code: 600000)
“SPD Structured Deposit Agreement IV”	the structured deposit agreement entered into between the Company and SPD Bank dated August 19, 2021 in relation to the purchase of structured deposit in the principal amount of RMB600 million
“SPD Structured Deposit Agreement VII”	the structured deposit agreement entered into between the Company and SPD Bank dated November 11, 2021 in relation to the purchase of structured deposit in the principal amount of RMB700 million

“SPD Structured Deposit Agreement VIII”	the structured deposit agreement entered into between the Company and SPD Bank dated November 19, 2021 in relation to the purchase of structured deposit in the principal amount of RMB400 million
“SPD Structured Deposit Agreements”	the SPD Structured Deposit Agreement VII and the SPD Structured Deposit Agreement VIII
“USD”	US dollar, the lawful currency of the United States of America
“%”	per cent.

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, November 19, 2021

*As of the date of this announcement, the Board comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive Directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.*

\* *For identification purpose only*